Autoimmune Diseases
Conditions
Keywords
therapeutic plasma exchange, meropenem, pharmacokinetic
Brief summary
Therapeutic plasma exchange (TPE) has been shown to be an important procedure for treatment of a variety of refractory immune complex disorders, such as Guillain-Barré syndrome and neuromyelitis optica. The intervention removes plasma, albumin, or some other substance. Meropenem is a broad-spectrum beta-lactam antimicrobial agent that is used for the treatment of serious nosocomial infections. Pathophysiological changes in patients on TPE can alter the pharmacokinetic (PK) patterns of coadministered antibiotics. This effect has an impact on the antimicrobial agents when paticipants are administered during the intervention. The aim of this study was to investigate the impact of TPE on meropenem PK.
Interventions
DRUGmeropenem
each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first TPE and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
Sponsors
Prince of Songkla University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* age≥ 18 years * no shock * hemoglobin ≥ 7 g/dl
Exclusion criteria
* pregnancy or breast-feeding female * history of hypersensitivity to carbapenems * renal replacement therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The plasma concentrations were measured at the following times: 0, 0.25, 0.5, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hour after the start of drug administration | 0-8 hours after the drug administration |
Secondary
| Measure | Time frame |
|---|---|
| Maximum plasma concentration [Cmax] | 0-8 hours after the drug administration |
| Minimum plasma concentration [Cmin] | 0-8 hours after the drug administration |
| Area under the plasma concentration versus time curve [AUC] | 0-8 hours after the drug administration |
| half-life [t1/2] | 0-8 hours after the drug administration |
Countries
Thailand
Contacts
Primary ContactSutep Jaruratanasirikul, M.D.
Backup Contactmonchana Nawakitrangsan, M.Pharm
Outcome results
None listed